Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status.
Alexander T CohenJanvi SahAmol D DhamaneTheodore LeeLisa RosenblattPatrick HlavacekBirol EmirAllison KeshishianHuseyin YuceXuemei LuoPublished in: Advances in therapy (2021)
Among older patients with VTE initiating apixaban or warfarin, higher rates of recurrent VTE and bleeding were observed in black patients and patients with lower SES. Apixaban had a lower risk of recurrent VTE, MB, and CRNMB compared to warfarin. Analyses of demographic and SES subgroups showed consistent findings.